GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH0) » Definitions » Cyclically Adjusted PB Ratio

Redhill Biopharma (STU:2RH0) Cyclically Adjusted PB Ratio : 0.00 (As of May. 31, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma Cyclically Adjusted PB Ratio?

As of today (2024-05-31), Redhill Biopharma's current share price is €0.402. Redhill Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €280.19. Redhill Biopharma's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Redhill Biopharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Redhill Biopharma's highest Cyclically Adjusted PB Ratio was 1.19. The lowest was 0.01. And the median was 0.14.

STU:2RH0's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.85
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Redhill Biopharma's adjusted book value per share data for the three months ended in Jun. 2023 was €0.813. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €280.19 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Redhill Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Redhill Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Cyclically Adjusted PB Ratio Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.33 0.02 -

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.02 0.01 - -

Competitive Comparison of Redhill Biopharma's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Cyclically Adjusted PB Ratio falls into.



Redhill Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Redhill Biopharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.402/280.19
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redhill Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Redhill Biopharma's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.813/128.7287*128.7287
=0.813

Current CPI (Jun. 2023) = 128.7287.

Redhill Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201309 66.398 98.790 86.520
201312 54.068 98.326 70.786
201403 122.612 99.695 158.321
201406 113.462 100.560 145.246
201409 105.744 100.428 135.543
201412 92.322 99.070 119.961
201503 126.028 99.621 162.851
201506 774.937 100.684 990.790
201509 1,857.021 100.392 2,381.197
201512 173.545 99.792 223.867
201603 1,551.840 100.470 1,988.310
201606 1,371.249 101.688 1,735.887
201609 113.188 101.861 143.043
201612 139.386 101.863 176.149
201703 1,292.566 102.862 1,617.604
201706 101.223 103.349 126.080
201709 66.332 104.136 81.997
201712 71.603 104.011 88.619
201803 55.157 105.290 67.436
201806 41.559 106.317 50.320
201809 53.539 106.507 64.710
201812 63.439 105.998 77.043
201903 52.253 107.251 62.717
201906 39.811 108.070 47.422
201909 29.255 108.329 34.764
201912 61.245 108.420 72.717
202003 22.400 108.902 26.478
202006 32.839 108.767 38.866
202009 26.050 109.815 30.537
202012 11.871 109.897 13.905
202103 38.189 111.754 43.990
202106 21.018 114.631 23.603
202109 7.494 115.734 8.335
202112 5.995 117.630 6.561
202203 -3.610 121.301 -3.831
202206 -7.079 125.017 -7.289
202209 -29.035 125.227 -29.847
202212 -19.610 125.222 -20.159
202303 0.692 127.348 0.700
202306 0.813 128.729 0.813

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Redhill Biopharma  (STU:2RH0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Redhill Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (STU:2RH0) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Redhill Biopharma (STU:2RH0) Headlines

No Headlines